<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In a retrospective study of 96 patients with a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> the FAB classification, Bournemouth score and other parameters were correlated with leukaemic transformation and survival </plain></SENT>
<SENT sid="1" pm="."><plain>Diagnosis was refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> (RA) in 7 patients, acquired idiopathic sideroblastic <z:hpo ids='HP_0001903'>anaemia</z:hpo> (AISA) in 2, <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) in 31, refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) in 34 and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t) in 22 </plain></SENT>
<SENT sid="2" pm="."><plain>Median survival for <z:hpo ids='HP_0000001'>all</z:hpo> patients was 37 weeks (RA and AISA 103, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> 67, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> 35, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t 27) </plain></SENT>
<SENT sid="3" pm="."><plain>Scoring according to the Bournemouth criteria showed significant differences in survival between groups A, B and C </plain></SENT>
<SENT sid="4" pm="."><plain>Of the separate variables, only percentage of bone marrow blasts and <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> level were prognostically significant </plain></SENT>
<SENT sid="5" pm="."><plain>A modified scoring system based upon these two variables was even more discriminative </plain></SENT>
<SENT sid="6" pm="."><plain>It proved to be particularly useful in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>, a subtype with a wide range of survival times </plain></SENT>
<SENT sid="7" pm="."><plain>Leukaemic transformation was seen in 39% (RA and AISA 0%, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> 30%, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> 39%, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t 75%) </plain></SENT>
</text></document>